2030 Regulations Trials 
DrugBank
MARCH 7, 2024
adults using obesity medications by 2030, further underlining the growing significance of this sector. On the other hand, Amgen revealed early-stage trial data on a promising once-a-month, weight loss medication, signaling its entry into this competitive arena. Goldman Sachs analysts anticipate a significant rise in the number of U.S.
FDA Law Blog: Biosimilars
JULY 10, 2024
Lenz, Principal Medical Device Regulation Expert — FDA’s Center for Devices and Radiological Health (CDRH) recently partnered with the Digital Medicine Society (DiMe) to host a two-day workshop to help advance the use of patient-generated health data (PGHD) to support improved clinical trials, medical device development, and regulatory science.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Vial
MAY 20, 2024
Distinguishing the Roles of Preclinical vs. Clinical CROs in Clinical Research Randomized clinical trials are the gold-standard of evidence-based medicine, representing the culmination of the long, arduous drug development pipeline. billion by 2030 at a compound annual growth rate (CAGR) of 7.5% between 2024 and 2030.
Agency IQ
MAY 10, 2024
BY RAYAN BHARGAVA, MSC | MAY 9, 2024 11:03 PM CDT Regulatory background Until recently, the EU had plans to halve pesticide reduction by 2030. The proposal for a regulation on the sustainable use of pesticides (SUR), however, died in European Parliament in November 2023. Much financial weight is thrown behind Ecophyto 2030.
DrugBank
MARCH 15, 2024
billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. Mounjaro distinguishes itself from other treatments on the market by being the first to simultaneously activate GIP and GLP-1 pathways, offering a novel approach to regulating blood sugars for people with Type 2 Diabetes.
Vial
FEBRUARY 15, 2024
Clinical trials play a crucial role in advancing medical breakthroughs, but effective management is essential to unlock their full potential. Pharmaceutical companies often face challenges in conducting clinical trials due to the need for substantial knowledge, time, and resources. over the forecast period (2022-2030).
Vial
FEBRUARY 23, 2024
billion and is expected to climb at a compound annual growth rate (CAGR) of 19.44% between 2023 and 2030. To learn about the history of these trial technologies and their adoption within the clinical research industry, read more here ! Factors contributing to digital patient portal usage An observational study by Janssen et al.
Expert insights. Personalized for you.
81 
Let's personalize your content